100.41
Axsome Therapeutics Inc stock is traded at $100.41, with a volume of 563.80K.
It is up +0.02% in the last 24 hours and down -2.85% over the past month.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
See More
Previous Close:
$100.39
Open:
$100.82
24h Volume:
563.80K
Relative Volume:
0.89
Market Cap:
$4.94B
Revenue:
$338.46M
Net Income/Loss:
$-310.96M
P/E Ratio:
-15.38
EPS:
-6.53
Net Cash Flow:
$-132.82M
1W Performance:
-2.09%
1M Performance:
-2.85%
6M Performance:
-4.50%
1Y Performance:
+19.29%
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Name
Axsome Therapeutics Inc
Sector
Industry
Phone
(212) 332-3241
Address
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Compare AXSM with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
AXSM
Axsome Therapeutics Inc
|
100.41 | 4.94B | 338.46M | -310.96M | -132.82M | -6.53 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
468.41 | 118.34B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
558.14 | 60.31B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
330.55 | 42.35B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
598.79 | 36.43B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
305.74 | 31.87B | 3.81B | -644.79M | -669.77M | -6.24 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-03-25 | Resumed | Morgan Stanley | Overweight |
Jun-03-25 | Initiated | Oppenheimer | Outperform |
Apr-07-25 | Initiated | Jefferies | Buy |
Feb-11-25 | Initiated | Deutsche Bank | Buy |
Dec-31-24 | Reiterated | Mizuho | Outperform |
Sep-03-24 | Initiated | Wells Fargo | Overweight |
Aug-06-24 | Upgrade | BofA Securities | Neutral → Buy |
Jul-22-24 | Initiated | Needham | Buy |
Apr-29-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Mar-19-24 | Initiated | Robert W. Baird | Outperform |
Feb-06-24 | Initiated | UBS | Buy |
Jan-25-24 | Initiated | RBC Capital Mkts | Outperform |
Dec-13-23 | Initiated | Citigroup | Buy |
Aug-08-23 | Upgrade | BofA Securities | Underperform → Neutral |
Jan-05-23 | Initiated | Piper Sandler | Neutral |
Nov-01-22 | Initiated | Loop Capital | Buy |
Sep-07-22 | Resumed | Mizuho | Buy |
Aug-10-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Jun-10-21 | Initiated | Berenberg | Buy |
Jan-08-21 | Initiated | Jefferies | Buy |
Dec-16-20 | Initiated | Mizuho | Buy |
Sep-29-20 | Initiated | BofA Securities | Underperform |
Sep-10-20 | Initiated | Morgan Stanley | Overweight |
Apr-28-20 | Reiterated | H.C. Wainwright | Buy |
Apr-14-20 | Initiated | Cowen | Outperform |
Dec-30-19 | Reiterated | H.C. Wainwright | Buy |
Dec-17-19 | Reiterated | H.C. Wainwright | Buy |
Dec-16-19 | Reiterated | Guggenheim | Buy |
Oct-16-19 | Initiated | Guggenheim | Buy |
Sep-18-19 | Initiated | William Blair | Outperform |
May-28-19 | Initiated | SunTrust | Buy |
May-23-19 | Reiterated | H.C. Wainwright | Buy |
Apr-08-19 | Initiated | SVB Leerink | Outperform |
Mar-15-19 | Reiterated | H.C. Wainwright | Buy |
Oct-03-16 | Resumed | Brean Capital | Buy |
Dec-15-15 | Initiated | Cantor Fitzgerald | Buy |
Dec-14-15 | Initiated | Ladenburg Thalmann | Buy |
View All
Axsome Therapeutics Inc Stock (AXSM) Latest News
Axsome Therapeutics Inc.’s Price Action Aligns with Quant SignalsTriple Digit Return Stock Predictions Released - metal.it
Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance
What makes Axsome Therapeutics Inc. stock price move sharplyStock Strategy Planner To Watch Now - jammulinksnews.com
Envestnet Asset Management Inc. Sells 10,086 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics (AXSM) to Release Earnings on Monday - MarketBeat
Why is Axsome Therapeutics Inc. stock attracting strong analyst attentionAchieve rapid portfolio growth with expert guidance - jammulinksnews.com
Royce & Associates LP Sells 6,743 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
What catalysts could drive Axsome Therapeutics Inc. stock higher in 2025Invest confidently with real-time data analysis - jammulinksnews.com
Does Axsome Therapeutics Inc. stock perform well during market downturnsGet timely alerts on market opportunities - jammulinksnews.com
Universal Beteiligungs und Servicegesellschaft mbH Makes New Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Cwm LLC Trims Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Y Intercept Hong Kong Ltd Makes New $1.49 Million Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
How strong is Axsome Therapeutics Inc. company’s balance sheetFree Market Dynamics Reports - jammulinksnews.com
Axsome Therapeutics Inc. Company’s Quarterly Earnings Growth: What the Numbers SayFree Stock Market Query - metal.it
Published on: 2025-07-27 23:41:07 - jammulinksnews.com
Is Axsome Therapeutics Inc. stock overvalued or undervaluedDynamic profit expansion - jammulinksnews.com
When is Axsome Therapeutics Inc. stock expected to show significant growth - jammulinksnews.com
How does Axsome Therapeutics Inc. generate profit in a changing economyUnprecedented profit potential - jammulinksnews.com
Knights of Columbus Asset Advisors LLC Sells 4,957 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Q3 EPS Estimate for Axsome Therapeutics Raised by Analyst - MarketBeat
Axsome Therapeutics: Navigating Setbacks with a Strong Pipeline and Analyst Confidence - AInvest
Axsome: Some Recent Setbacks, Some Recent Wins — Still A Buy (NASDAQ:AXSM) - Seeking Alpha
Axsome Therapeutics (NASDAQ:AXSM) Shares Down 5.6%Here's Why - MarketBeat
Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline - ADVFN Brasil
Why Axsome Therapeutics Inc. stock is on top investor watchlistsSuperior stock selection - jammulinksnews.com
What analysts say about Axsome Therapeutics Inc. stockOutstanding capital growth - Autocar Professional
Axsome Therapeutics Inc. Stock Analysis and ForecastRapid growth trajectories - PrintWeekIndia
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stake Raised by Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. - MarketBeat
RBC Capital Sticks to Their Buy Rating for Axsome Therapeutics (AXSM) - The Globe and Mail
New York State Common Retirement Fund Has $3.92 Million Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Is Axsome Therapeutics Inc. stock overhyped or has real potentialUnstoppable trading performance - jammulinksnews.com
How high can Axsome Therapeutics Inc. stock price go in 2025Breakthrough investment results - jammulinksnews.com
How To Trade (AXSM) - news.stocktradersdaily.com
Axsome Therapeutics Settles SUNOSI (Solriamfetol) Patent Litigation With Hetero Labs Ltd. - 富途牛牛
Is This Stock a Buy After Soaring by 20% in 1 Day? - AOL.com
2 Top Stocks I Wouldn't Hesitate to Invest $1,000 in Right Now - MSN
Legato Capital Management LLC Buys New Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today - 富途牛牛
Is Axsome Therapeutics Inc. a good long term investmentGame-changing returns - Autocar Professional
Leerink Partners Keeps Bullish Stance on Axsome Therapeutics with Buy Rating - AInvest
Lindbrook Capital LLC Cuts Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Optimistic Outlook for Axsome Therapeutics: Promising Pipeline and Potential Sales Growth Drive Buy Rating - TipRanks
Axsome Therapeutics Breaks Below 200-Day Moving AverageNotable for AXSM - Nasdaq
What drives Axsome Therapeutics Inc. stock priceUnprecedented profit potential - jammulinksnews.com
Readystate Asset Management LP Invests $6.95 Million in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
ALKS Down Despite Positive Top-Line Data From Narcolepsy Study - The Globe and Mail
Axsome Therapeutics stock rating reiterated by Cantor Fitzgerald - Investing.com Canada
Axsome Therapeutics Inc Stock (AXSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Axsome Therapeutics Inc Stock (AXSM) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Murdock Hunter R. | General Counsel |
Jun 23 '25 |
Option Exercise |
29.91 |
6,014 |
179,879 |
6,014 |
Murdock Hunter R. | General Counsel |
Jun 20 '25 |
Sale |
102.47 |
7,500 |
768,525 |
0 |
Murdock Hunter R. | General Counsel |
Jun 23 '25 |
Sale |
100.12 |
6,014 |
602,122 |
0 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):